ClinicalTrials.gg
CompletedNCT05014204REGENT-1-USUpdated Dec 22, 2025Results posted

Safety and Feasibility of Novel Therapy for Duodenal Mucosal Regeneration for Type II Diabetes

An interventional study of The Endogenex Device in Diabetes, Diabetes Type 2 and Diabetes Mellitus, Type 2, sponsored by Endogenex, Inc.. Completed at 3 sites in United States. Open to participants aged 22 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-12-22.

Primary conditionDiabetes Mellitus, Type 2Registry: Diabetes MellitusReclassifiedWhy we changed it
Registry
Diabetes Mellitus — the first condition term the registry derived for this study.
ClinicalTrials.gg
Diabetes Mellitus, Type 2
Why
  1. The study's listed conditions name Diabetes Mellitus, Type 2, a narrower term within Diabetes Mellitus.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Endogenex, Inc. · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
22 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 3,308 studies in Diabetes Mellitus, Type 2 with a site in United States — 345 open to participants now, 479 under way, 51 of them phase 3. Diabetes Mellitus, Type 2 · United States.

Enrollment
2,493rd of 2,961
20 · median 90
Started
2021
with 171 others
No phase
1,242 of 3,308
200 open now
Registered
2,530th of 3,308
by date

Among the 3,308 studies in Diabetes Mellitus, Type 2 with a site in United States, this one is the 2,493rd largest by enrollment of the 2,961 interventional ones that give a count, is one of 172 that started in 2021, is one of 1,242 with no phase, and was the 2,530th registered.

Diabetes Mellitus, Type 2

10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

345 of the 3,308 studies in Diabetes Mellitus, Type 2 with a site in United States are open now. Recruiting first, the newest first:

340 more — sign in →

All 345 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 22 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 3,308 studies in Diabetes Mellitus, Type 2 with a site in United States, or all of them as a file.
02

Study summary

This is a multi-center, open-label study to assess the feasibility and preliminary safety of the Endogenex Device for endoscopic duodenal mucosal regeneration in patients with type 2 Diabetes inadequately controlled on 2-3 non-insulin glucose-lowering medications.

Read the detailed description

Individuals who sign the informed consent will be screened for study eligibility. Eligible participants will be treated with the Endogenex procedure and followed up for 48 weeks.

03

Conditions studied

  • Diabetes
  • Diabetes Type 2
  • Diabetes Mellitus, Type 2
  • Glucose Metabolism Disorders
  • Metabolic Disease
  • Endocrine System Diseases
  • Diabetes Mellitus

Keywords

  • Endoscopy
  • type 2 diabetes
04

In context

Diabetes Mellitus, Type 2 Reclassified

10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

This study's enrollment of 20 is below the median of 80 across 8,372 interventional studies indexed under Diabetes Mellitus, Type 2.

Browse Diabetes Mellitus, Type 2 studies →

Lead sponsor

Endogenex, Inc. is the lead sponsor of 6 studies on the registry; 3 are open to participants now.

Compared within Diabetes Mellitus, Type 2, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Diabetes Mellitus. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
22 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. 22- 65 years of age
  2. Current diagnosis of T2D
  3. History of T2D for at least 3 years and less than or equal to 10 years
  4. of 7.5-10.0%, inclusive
  5. 24-40 kg/m2, inclusive
  6. On two to three non-insulin glucose lowering mediations, with one at maximum tolerated dose and another at half-maximum dose at least, with no changes in medication for at least 12 weeks prior to baseline visit prior to baseline visit
  7. History of failed attempt to reach glycemic goal by lifestyle modifications
  8. Weight stability (defined as a \< 5% change in body weight) for at least 12 weeks prior to the screening visit
  9. Agree not to donate blood during participation in the study.
  10. Able to comply with study requirements and understand and sign the Form
  11. Women of must be using an acceptable method of throughout the study
  12. Willing and able to use CGM for the duration of the study and comply with study visits and study tasks as required per protocol.
  13. Proof of COVID 19 vaccination.

Exclusion criteria

Exclusion Criteria:

  1. Diagnosed with type 1 diabetes
  2. History of diabetic ketoacidosis or hyperosmolar nonketotic coma
  3. Probable insulin production failure, defined as overnight fasting C-peptide serum \<1 ng/mL (333pmol/l).
  4. Previous use of any types of insulin for >1 month (at any time, except for treatment of gestational diabetes) in last 2 years.
  5. Current use of insulin
  6. Hypoglycemia unawareness
  7. History of ≥1 severe hypoglycemia episode (defined by needing for third-party assistance) in past 6 months from the screening visit
  8. Known disease, as evidenced by a positive anti-glutamic acid decarboxylase (GAD) test, including but not limited to celiac disease, or pre-existing symptoms of systemic lupus erythematosus, scleroderma or other autoimmune connective tissue disorder. (Participants with adequately controlled primary hypothyroidism may be included).
  9. Previous GI surgery that has changed GI anatomy or could limit treatment of the duodenum, such as Billroth 2, Roux-en-Y gastric bypass, gastric band or other similar procedures or conditions.
  10. Known history of a structural or functional disorder of the upper GI tract that may impede passage of the device through the upper GI tract or increase risk of tissue damage during an endoscopic procedure, including esophagitis, stricture/stenosis, varices, diverticula, or other disorder of the esophagus, stomach and duodenum.
  11. Active H. pylori infection (Participants with active H. pylori may continue with the screening process if they are treated with an appropriate antibiotic regimen)
  12. History of, or gastrointestinal symptoms suggestive of gastroparesis.
  13. Acute gastrointestinal illness in the previous 7 days
  14. Known history of irritable bowel syndrome, radiation enteritis or other inflammatory bowel disease, such as Crohn's disease and Celiac disease
  15. History of chronic or acute pancreatitis.
  16. Known active hepatitis or active liver disease other than NASH/NAFLD.
  17. Alcoholic liver disease, as indicated by ANI > 0
  18. Current use of anticoagulation therapy (such as warfarin) that cannot be discontinued for 7 days before and 14 days after the procedure.
  19. Current use of P2Y12 inhibitors (clopidogrel, prasugrel, ticagrelor) that cannot be discontinued for 14 days before and 14 days after the procedure.
  20. Unable to discontinue non-steroidal anti-inflammatory drugs (NSAIDs) during treatment through 4 weeks following the procedure. Use of acetaminophen and low dose aspirin is allowed.
  21. Use of systemic (excluding topical or ophthalmic application or inhaled forms) for more than 10 consecutive days within 12 weeks prior to the baseline visit.
  22. Use of drugs known to affect GI motility (e.g. Metoclopramide)
  23. Use of weight loss medications such as Meridia, Xenical, Phentermine or over-the-counter weight loss medications (prescription medication)
  24. Currently taking, or unable to stop taking dietary supplements or herbal agents, including vitamin C or multivitamins containing vitamin C at >500 mg per day, multivitamins containing biotin (vitamin B7), and supplements for hair, skin, and nail growth. Multivitamins not containing biotin are permitted.
  25. Persistent anemia, defined as \<10 g/dL.
  26. Known history of hemoglobinopathy.
  27. Known history of blood donation or transfusion within 3 months prior to the Screening Visit.
  28. Known history of cardiac arrythmia
  29. Significant cardiovascular disease, including known history of valvular disease, or myocardial infarction, heart failure, , or stroke within 6 months prior to the Screening Visit.
  30. Estimated (eGFR) ≤ 60 ml/min/1.73m2 (estimated by MDRD).
  31. Known status, including but not limited to individuals who have undergone organ transplantation, chemotherapy, or radiotherapy within the past 12 months, who have leukopenia, who are positive for the (HIV) or whose immune status makes the participant a poor candidate for clinical trial participation in the opinion of the investigator.
  32. History of secondary hypothyroidism or inadequately controlled primary hypothyroidism (TSH value outside the normal range at screening)
  33. With any implanted electronic devices or duodenal metallic implants
  34. Not a candidate for upper GI endoscopy or general anesthesia.
  35. Active illicit substance abuse or alcoholism (>2 drinks/day regularly)
  36. Active within the last 5 years (excluding non-melanoma skin cancers)
  37. Women breastfeeding
  38. Participating in another ongoing clinical trial of an drug or device.
  39. Any other mental or physical condition which, in the opinion of the study investigator, makes the participant a poor candidate for clinical trial participation.
  40. Critically ill or has a \<3 years

    Additional exclusion criteria to be confirmed during the screening process:

  41. \< 7.5% or > 10% at baseline visit
  42. Any severe hypoglycemic event since the screening visit
  43. CGM readings \<54 mg/dl in more than 1% of time by CGM since the screening visit
  44. CGM readings > 360 mg/dL in more than 1% of time
  45. Mean of 3 separate blood pressure measurements >180 mmHg (systolic) or >100 mmHg (diastolic)
  46. Women of with a positive urine pregnancy test at baseline visit
  47. LA Grade C or greater esophagitis on endoscopy
  48. Abnormalities of the GI tract preventing endoscopic access to the duodenum
  49. Anatomic abnormalities in the duodenum that would preclude the completion of the treatment procedure, including tortuous anatomy
  50. Endoscopic observation of upper gastrointestinal abnormality such as ulcers, polyps, varices, strictures, congenital or intestinal telangiectasia
  51. Any other anatomical or endoscopic abnormalities/characteristics that, in the opinion of the investigator, would preclude safe use of the investigational device or procedure
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

06

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    Interventional

    All eligible patients will receive the endoscopic Endogenex procedure.

    Device: The Endogenex Device

Interventions

  • DeviceThe Endogenex Device

    The Endogenex device is designed to induce duodenal mucosal regeneration using pulsed electric field. The Endogenex procedure is a non-surgical, endoscopic procedure.

07

What researchers measure

Primary outcomes

  1. Participants Experiencing Device- or Procedure-Related Serious Adverse Events (SAE)

    Number of participants experiencing device- or procedure-related serious adverse events (SAE)

    Time frame: 12 weeks post-procedure

Secondary outcomes

  1. Mean HbA1c by Follow-up Visit

    Mean HbA1c by Post Procedure Follow-up Visits

    Time frame: at 4,12, 24, and 48 Weeks Post Procedure

  2. Mean Fasting Plasma Glucose (FPG) by Visit

    Mean Fasting Plasma Glucose (FPG) at Post Procedure Follow-up Visit

    Time frame: Follow-up at 4,12, 24, 36, and 48 weeks post procedure

  3. Mean Weight by Follow-up Visit

    Mean weight by Post Procedure Follow-up Visit

    Time frame: Follow-up at 4,12, 24, 36, and 48 weeks post procedure

Other outcomes

  1. Procedural Success

    Percentage of participants with successful DMR procedure

    Time frame: At the time of procedure

  2. Procedural Time

    Time between catheter insertion to catheter removal

    Time frame: At the time of procedure

08

Results

Posted Dec 22, 2025
Limitations and caveats
This pilot study was designed to assesses the initial safety of the Endogenex device in participants with type 2 diabetes. Due to the small sample size, no formal hypothesis testing was performed. Descriptive statistics are reported using mean and standard deviations.

Participant flow

Participants were recruited from 3 study sites in the US. Twenty participants were enrolled (i.e. received Endogenex treatment). Two participants did not complete the study due to patient withdrawal and physician withdrawal to relocation.

Participant flow — Overall Study
MilestoneInterventional Arm- Endogenex (PEF) Treatment
Started20
Completed18
Not completed2
Withdrew: Withdrawal by subject1
Withdrew: Physician decision1

Outcome measures

PrimaryParticipants Experiencing Device- or Procedure-Related Serious Adverse Events (SAE)

Number of participants experiencing device- or procedure-related serious adverse events (SAE)

Time frame:
12 weeks post-procedure
Reported as:
Number · Number of Participants with related SAE
Participants Experiencing Device- or Procedure-Related Serious Adverse Events (SAE)
Number of Participants with related SAEInterventional Arm- Endogenex (PEF) Treatment
Participants Experiencing Device- or Procedure-Related Serious Adverse Events (SAE)0
SecondaryMean HbA1c by Follow-up Visit

Mean HbA1c by Post Procedure Follow-up Visits

Time frame:
at 4,12, 24, and 48 Weeks Post Procedure
Reported as:
Mean · HbA1c %
Mean HbA1c by Follow-up Visit
HbA1c %Interventional Arm- Endogenex (PEF) Treatment
Mean HbA1c at Week 4 Post Procedure7.2 ± 0.7
Mean HbA1c at Week 12 Post Procedure6.7 ± 0.7
Mean HbA1c at Week 24 Post Procedure6.9 ± 1.1
Mean HbA1c at Week 36 Post Procedure7.0 ± 0.7
Mean HbA1c at Week 48 Post Procedure7.2 ± 0.8
SecondaryMean Fasting Plasma Glucose (FPG) by Visit

Mean Fasting Plasma Glucose (FPG) at Post Procedure Follow-up Visit

Time frame:
Follow-up at 4,12, 24, 36, and 48 weeks post procedure
Reported as:
Mean · mg/dL
Mean Fasting Plasma Glucose (FPG) by Visit
mg/dLInterventional Arm- Endogenex (PEF) Treatment
Mean FPG at Week 4 post procedure140.1 ± 28.6
Mean FPG at Week 12 post procedure155.7 ± 28.8
Mean FPG at Week 24 post procedure155.9 ± 42.7
Mean FPG at Week 36 post procedure150.8 ± 24.2
Mean FPG at Week 48 at post procedure161.6 ± 37.0
SecondaryMean Weight by Follow-up Visit

Mean weight by Post Procedure Follow-up Visit

Time frame:
Follow-up at 4,12, 24, 36, and 48 weeks post procedure
Reported as:
Mean · lbs
Mean Weight by Follow-up Visit
lbsInterventional Arm- Endogenex (PEF) Treatment
Mean Weight at Week 4 Post Procedure215.6 ± 38.1
Mean Weight at Week 12 Post Procedure209.3 ± 36.1
Mean Weight at Week 24 Post Procedure214.9 ± 40.3
Mean Weight at Week 36 Post Procedure213.3 ± 41.1
Mean Weight at Week 48 Post Procedure217.8 ± 41.7
Other pre-specifiedProcedural Success

Percentage of participants with successful DMR procedure

Time frame:
At the time of procedure
Reported as:
Count of participants · Participants
Procedural Success
ParticipantsInterventional Arm- Endogenex (PEF) Treatment
Procedural Success20
Other pre-specifiedProcedural Time

Time between catheter insertion to catheter removal

Time frame:
At the time of procedure
Reported as:
Mean · minutes
Procedural Time
minutesInterventional Arm- Endogenex (PEF) Treatment
Procedural Time82.9 ± 20.1

Adverse events

Collected over Enrollment through study completion at 48 weeks. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Interventional Arm- Endogenex (PEF) Treatment0/20 (0%)5/20 (25%)19/20 (95%)
Most frequent serious events
Most frequent serious events
EventInterventional Arm- Endogenex (PEF) Treatment
NephrolithiasisRenal and urinary disorders1/20
Acute cholecystitisHepatobiliary disorders1/20
CholecystectomyHepatobiliary disorders1/20
Malignant MelanomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/20
Colon AdenomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/20
Most frequent other events
Showing 10 of 37
Most frequent other events
EventInterventional Arm- Endogenex (PEF) Treatment
Oropharyngeal PainGastrointestinal disorders14/20
ConstipationGastrointestinal disorders4/20
COVID-19Infections and infestations3/20
Upper abdominal PainMusculoskeletal and connective tissue disorders2/20
Back PainMusculoskeletal and connective tissue disorders2/20
ConjunctivitisInfections and infestations2/20
GastroenteritisGastrointestinal disorders2/20
NasopharyngititisInfections and infestations2/20
NauseaGastrointestinal disorders2/20
EsophagititisGastrointestinal disorders2/20

Baseline characteristics

Age, Customized
Age, Customized(years)Interventional Arm- Endogenex (PEF) Treatment
Age54.4 ± 7.8
Sex: Female, Male
Sex: Female, Male(Participants)Interventional Arm- Endogenex (PEF) Treatment
Female5
Male15
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Interventional Arm- Endogenex (PEF) Treatment
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American0
White20
More than one race0
Unknown or Not Reported0
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Interventional Arm- Endogenex (PEF) Treatment
Hispanic or Latino0
Not Hispanic or Latino20
Unknown or Not Reported0
HbA1c (%)
HbA1c (%)(%)Interventional Arm- Endogenex (PEF) Treatment
Mean8.3 ± 0.54
Duration of Diabetes (years)
Duration of Diabetes (years)(years)Interventional Arm- Endogenex (PEF) Treatment
Mean6.7 ± 2
BMI (kg/m²)
BMI (kg/m²)(kg/m²)Interventional Arm- Endogenex (PEF) Treatment
Mean32.4 ± 4.3
Weight (lbs)
Weight (lbs)(lbs)Interventional Arm- Endogenex (PEF) Treatment
Mean224 ± 39
09

Study locations

3 sites
  • University of Southern California
    Los Angeles, California 90033, United States
  • Cuyuna Regional Medical Center
    Crosby, Minnesota 56441, United States
  • Mayo Clinic
    Rochester, Minnesota 55905, United States
10

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2021 to primary completion in May 2024, 31 months.

Results were first posted in Dec 2025, 1 year 6 months after primary completion.

Of 177 industry-sponsored interventional studies with no phase under Diabetes Mellitus, Type 2, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 29. This study's 31 months is above that.

Counting every sponsor, half of 2,255 studies reached it within 21 months; a quarter within 10 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 13, 2021
First posted
Aug 20, 2021
StartActual
Oct 29, 2021
Primary completionActual
May 29, 2024
CompletionActual
May 29, 2025
Results first posted
Dec 22, 2025
Last update
Dec 22, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 22, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT05014204
Lead sponsor
Endogenex, Inc.
Responsible party
Sponsor
First posted
Aug 20, 2021
Start date
Oct 29, 2021
Primary completion
May 29, 2024
Completion
May 29, 2025
Results posted
Dec 22, 2025
Last update
Dec 22, 2025

Study contacts

Daniel DeMarco, MD
study chair · Baylor Scott and White Health

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion